Unimedic Pharma AB enter a collaboration with Consilient Health Limited for the launch of Melatonin oral solution in the UK

Unimedic Pharma AB have signed a license and supply agreement with Consilient Health for the launch of Melatonin 1 mg/ml oral solution in the UK. On November 16, 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) granted Melatonin Consilient Health approval for insomnia in children with ADHD, as well as for short-term jet-lag therapy in adults.

In this partnership, Consilient Health is the marketing authorization holder of the product and carry the responsibility for marketing, distribution, and sales in the UK, while Unimedic is responsible for the manufacture and delivery of the product.

Anna Linton, CEO of Unimedic says “We are truly happy to enter a close partnership with Consilient Health and that healthcare professionals in the UK now are able to treat insomnia in children and adolescents with ADHD with a licensed Melatonin oral solution.”

About Melatonin 1 mg/ml Oral solutionAhmed Al-Derzi, CEO & Co-Founder of Consilient Health stated: “Consilient Health is pleased to announce this collaboration with Unimedic AB.The imminent launch of Melatonin Consilient Health is further evidence of Consilient Health’s continued commitment to bringing new affordable medicines to its UK customers.”

About Melatonin 1 mg/ml Oral solution

Melatonin Consilient Health contains the active substance melatonin, which is a hormone produced naturally by the body. The hormone helps regulate the body’s day- and night rhythm. Melatonin Consilient Health is approved for insomnia in children and adolescents (6-17 years of age) with attention deficit hyperactivity disorder (ADHD) where healthy sleeping routines has not worked well enough, and short-term treatment of jet lag in adults.

About Unimedic 

Unimedic is a fully integrated Swedish Specialist Pharmaceutical Company with broad experience in developing pharmaceuticals, contract manufacturing as well as distribution and sales of pharmaceuticals. Unimedic Pharma AB commercialize proprietary, acquired, licensed and unlicensed pharmaceuticals, as well as extemporaneous formulations. Unimedic AB is a full-service Contract Development and Manufacturing Organization (CDMO) for pharmaceutical companies. Unimedic AB specializes in liquid pharmaceuticals of both sterile and non-sterile production.

Unimedic is a wholly owned subsidiary to MedCap AB (publ), listed on Nasdaq Stockholm Mid Cap.

About Consilient Health

Consilient Health works with reputable developers and manufacturers to register, promote and distribute high quality prescription pharmaceuticals at affordable prices. Our expertise, experience, partnerships and commercialisation track record, combined with our agile management team enable us to be the partner of choice in our markets.